drugset / Trial / NCT03449524
PRIMEx - A Study of 2 Doses of Oral CXA-10 in Pulmonary Arterial Hypertension (PAH)
Phase 2
Terminated
69 enrolled
Complexa, Inc.
Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute) · collabCardiovascular Clinical Sciences Inc · collabInnovative Analytics · collabMedpace, Inc. · collabMicroConstants · collabPhilips Healthcare · collab
RandomizedParallel-groupQuadruple-blindTreatment
Summary
This is a multicenter double-blind, placebo-controlled study to evaluate the safety, efficacy and pharmacokinetics of 2 doses of CXA-10 on stable background therapy in 96 subjects 18 to 80 years of age with PAH.
Timeline
- Start
- 2018-08-01
- Primary completion
- 2020-08-05
- Completion
- 2020-08-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | CXA-10 | Small molecule | 75 mg | Oral |
| Comparator | CXA-10 | Small molecule | 150 mg | Oral |